Neuroprotection in Alzheimer's Disease

Edited by Illana Gozes, Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Israel   Features:

• Comprehensive reference detailing neuroprotection in Alzheimer’s Disease, with details on nerve cell protection and new advances in disease management
• Combines the knowledge and points-of-view of both medical doctors and basic scientists, putting the subject at the forefront for further clinical development
• Edited by one of the leading researchers in Alzheimer’s Disease

• Dedication
• List of Contributors
• Acknowledgments
• Chapter 1: Introduction
• Chapter 2: Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer’s Disease
  • Abstract
  • Introduction
  • Global health care burden of Alzheimer’s disease: epidemiological data
  • Etiopathogenesis of Alzheimer’s disease: what do we know?
  • Therapeutic approaches to Alzheimer’s disease: the promises, the failures, and the future
  • Neural regeneration-based therapeutic approach for AD: the rationale, the promise, and the progress
  • Neurotrophic factor small-molecule mimetics for Alzheimer’s disease
  • Enhancement of neurogenesis and memory by CNTF small-molecule mimetics
  • CNTF-derived neurogenic/neurotrophic compound, P021, can exert a disease-modifying effect in a transgenic mouse model of AD
  • Summary and conclusions
• Chapter 3: Animal Models of Alzheimer’s Disease
  • Abstract
  • Introduction
  • The genetics of Alzheimer’s disease
  • Transgenic models of amyloidogenesis
  • Amyloid precursor protein transgenic mice
  • PDAPP transgenic mice
  • Tg2576 transgenic mice
  • APP23 transgenic mice
  • J20 transgenic mice
  • APP knock-in transgenic mice
  • APP/PS1 transgenic mice
  • 5xFAD transgenic mice
  • Tau transgenic mice
  • Tau tg mice under tau promoter
  • 3xTg transgenic mice
  • Animal models for late onset of AD
  • Nonmouse models
  • Studies in nematodes
  • Studies in fruit flies
  • Nontransgenic models for the study of AD
  • How to choose the right model?
  • Summary
  • Acknowledgment
• Chapter 4: Mechanisms of Neuronal Microtubule Loss in Alzheimer’s Disease
  • Abstract
  • Introduction
  • Studies on Alzheimer’s brain and animal models
  • Are microtubules destabilized in the Alzheimer’s brain?
  • Mechanisms of microtubule loss in the Alzheimer’s brain
  • Strategies for treatment
  • Acknowledgments
• Chapter 5: Tau-Centric Therapies for Treating Alzheimer’s Disease
  • Abstract
  • Introduction
  • Tau-centric therapeutic strategy 1: targeting tau phosphorylation
  • Tau-centric therapeutic strategy 2: targeting microtubule destabilization
  • Tau-centric therapeutic strategy 3: targeting tau aggregation
  • Conclusions
• Chapter 6: The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity
  • Abstract
  • Introduction
  • Tau oligomers as a therapeutic target
  • Naturally occurring small molecules
  • Synthetic small molecules
  • Small molecules with broad antiamyloid properties
  • Concluding remarks
  • Acknowledgments
• Chapter 7: A Novel Neuroprotection Target With Distinct Regulation in Stroke and Alzheimer’s Disease
  • Abstract
  • Introduction
  • Alzheimer’s disease
  • Vascular dementia
  • Excitotoxicity
  • Kidins220/ARMS
  • Treatments for neuroprotection in acute versus chronic excitotoxicity
• Chapter 8: Sirtuin Modulation as Novel Neuroprotective Strategy for Alzheimer’s Disease
  • Abstract
  • Sirtuin protein family
  • Function and pathologic relevance of the mammalian sirtuins
  • Pharmacological activators and inhibitors of sirtuins
  • Sirtuins involvement in aging and longevity
  • Sirtuins and age-related diseases
  • Sirtuins and neurodegeneration
  • Sirtuins and Alzheimer’s disease
• Chapter 9: Rescue of Neurons by Resolving Inflammation
  • Abstract
  • Introductory remark: dysfunction of prohomeostasis as a pathogenic mechanism
  • Inflammation and its resolution
  • Evidence for inflammation in Alzheimer’s disease
  • Chronic inflammation
  • Dysfunction of Resolution in Alzheimer’s Disease
  • Dysfunction of resolution in the nervous system and Alzheimer’s disease as a target for therapeutic intervention
  • Concluding remarks
• Chapter 10: Targeting Transition Metals for Neuroprotection in Alzheimer’s Disease
  • Abstract
  • Introduction
  • Natural history of Alzheimer’s disease
  • Metals in the mechanisms of neurodegeneration and strategies for neuroprotection
  • Conclusions
• Chapter 11: Multifunctional Effects of Human Serum Albumin Toward Neuroprotection in Alzheimer Disease
  • Abstract
  • Introduction
  • Human serum albumin
  • Production sites and de novo synthesis
  • Structure and function
  • Protective properties of HSA
  • Therapeutic approaches based on HSA
  • HSA implication in the dynamics of Aß pathology
  • HSA as a potential therapeutic approach for AD
  • The interplay between ICV infusion of HSA and AD pathologies
  • Conclusions
• Chapter 12: RGS2 and SIRT1 Link Renin Angiotensin Aldosterone System to Alzheimer’s Disease
  • Abstract
  • Need for presymptomatic AD biomarkers
  • Searching early AD biomarkers by peripheral blood transcriptomics
  • RGS2 (regulator of G-protein signaling 2)
  • SIRT1 (Sirtuin 1)
  • Alzheimer’s disease and renin-angiotensin-aldosterone system
  • RGS2 and SIRT1 in renin-angiotensin-aldosterone system pathways
  • Conclusions
  • Acknowledgments
• Chapter 13: Neuroprotective Drug Development: The Story of ADNP, NAP (Davunetide), and SKIP
  • Abstract
  • Introduction: the discovery of ADNP
  • ADNP-the Alzheimer’s disease connection
  • NAP
  • SKIP
  • Patient stratification: ADNP as an AD diagnostic marker (Malishkevich et al., 2015b)
  • Epilog
  • Acknowledgments
• Author Index
• Subject Index